International Journal of Pharma Insight Studies

Nanotechnology in Drug Delivery Systems

Dr. John M. Allen [1*], Dr. Priya R Cullis [2], Dr. Zhiqiang Guo [3]
[1] Department of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
[2] Institute for Drug Delivery and Nanomedicine, University of Victoria, Victoria, BC, Canada
[3] Department of Biomedical Engineering, Zhejiang University, Hangzhou, China

* Corresponding Author: **Dr. John M. Allen**

Article Info

Volume: 01
Issue: 01
January-February 2024
Received: 02-01-2024
Accepted: 20-02-2024
Page No: 13-16

Abstract
Nanotechnology has revolutionized the field of drug delivery, enabling more efficient, targeted, and controlled release of therapeutic agents. This article explores the role of nanotechnology in drug delivery systems, highlighting its potential for overcoming conventional drug delivery limitations. Various nanomaterials such as nanoparticles, liposomes, and dendrimers are discussed in the context of their applications in drug delivery. The paper also covers advancements in targeting specific tissues, controlled release mechanisms, and the challenges faced in clinical implementation. This review provides insights into the future directions of nanotechnology-based drug delivery systems and their potential to enhance patient care.

Keywords: Nanotechnology, Drug Delivery Systems, Nanomaterials, Controlled Release, Targeted Therapy, Nanoparticles, Liposomes, Dendrimers

Introduction

The rapid advancement of nanotechnology has significantly impacted various fields, particularly in medicine. Drug delivery systems (DDS) are one of the most promising applications of nanotechnology, offering a way to overcome challenges associated with traditional drug delivery methods. Conventional drug delivery methods often face issues such as poor bioavailability, limited drug targeting, and non-specific distribution, leading to side effects and inefficiency. Nanotechnology, with its unique properties at the nanoscale, has provided innovative solutions to these problems, enabling precise control over drug release and enhanced therapeutic effects.

Nanomaterials used in drug delivery systems are engineered at the molecular or nanoscale level, allowing them to interact with biological systems in ways that conventional systems cannot. These materials include nanoparticles, liposomes, dendrimers, and nanogels, among others. Their small size, high surface area, and ability to encapsulate drugs enable targeted delivery, reduced toxicity, and controlled release of therapeutic agents. This review aims to examine the role of nanotechnology in drug delivery, focusing on the types of nanomaterials used, their methods of preparation, and their potential for clinical applications.

Materials and Methods

Nanomaterials for Drug Delivery Systems

Several nanomaterials have been developed and employed for drug delivery, each with distinct advantages depending on the therapeutic application. The key nanomaterials include:

1. **Nanoparticles**: These are solid colloidal particles made from lipids, polymers, or inorganic materials. Nanoparticles can encapsulate both hydrophobic and hydrophilic drugs, protecting them from degradation while ensuring controlled release. They offer advantages such as enhanced drug stability and the ability to cross biological barriers.
2. **Liposomes**: Liposomes are lipid-based vesicles that can carry both hydrophilic and hydrophobic drugs. Their composition allows for increased drug encapsulation and targeted delivery. Liposomes have been extensively studied for the delivery of anticancer drugs, vaccines, and other therapeutic agents.
3. **Dendrimers**: Dendrimers are highly branched, tree-like macromolecules that can be precisely engineered for drug delivery. They have a high surface area and can encapsulate multiple drugs or conjugate targeting ligands, improving drug stability and bioavailability.

4. **Nanogels**: Nanogels are three-dimensional networks of cross-linked polymers that can hold large quantities of drugs within their structure. These materials are particularly useful for controlled release and can be modified to release drugs in response to external stimuli such as pH or temperature changes.

Preparation Techniques

The preparation of nanomaterials for drug delivery involves various methods, each suited to the specific material and desired properties. Some of the common techniques include:

1. **Solvent Evaporation:** This method is often used for the preparation of polymeric nanoparticles and liposomes. In this process, a drug is dissolved in a solvent, which is then evaporated to form nanoparticles that encapsulate the drug.
2. **Emulsification:** Emulsification is commonly used for creating lipid-based nanocarriers like liposomes. The drug is dissolved in the aqueous phase, while lipids are dispersed in an organic phase. The two phases are mixed, and the solvent is evaporated to form stable emulsions.
3. **Self-assembly:** Nanomaterials like dendrimers and nanogels can be created through self-assembly processes, where molecules spontaneously organize themselves into desired nanostructures under specific conditions.
4. **Nanoprecipitation:** In this method, a polymer or drug is dissolved in a solvent, which is then rapidly added to a non-solvent, resulting in the precipitation of nanoparticles.

Results

Nanotechnology-based drug delivery systems have shown remarkable success in preclinical and clinical studies. The results demonstrate significant improvements over traditional drug delivery methods in terms of bioavailability, targeted delivery, and reduced side effects. Below are the key results observed from the use of various nanomaterials in drug delivery?

1. **Nanoparticles:** Studies have shown that nanoparticles improve the solubility of hydrophobic drugs and enhance their therapeutic effect. For example, paclitaxel-loaded nanoparticles have been found to significantly increase the drug's bioavailability compared to traditional formulations. Furthermore, nanoparticles can be engineered to target specific tissues, reducing off-target effects.
2. **Liposomes:** Liposomal drug formulations have demonstrated enhanced pharmacokinetics and a decrease in drug toxicity. A study involving liposomal doxorubicin (Doxil) showed better tumor-targeting ability and fewer side effects compared to free doxorubicin. This has made liposomal formulations highly effective for cancer therapy.
3. **Dendrimers:** Dendrimers are known for their highly branched structure, which allows for the encapsulation of multiple drug molecules or the addition of targeting ligands. Research on dendrimer-based drug delivery systems has shown their potential in targeting cancer cells, delivering drugs with high precision, and improving drug efficacy.
4. **Nanogels:** Nanogels are increasingly being used for controlled drug release. One notable result is the use of thermoresponsive nanogels for insulin delivery, where the gel swells in response to body temperature, releasing the drug in a controlled manner. This has applications in diabetes management.
5. **In Vivo and Clinical Trials:** Clinical studies of nanotechnology-based drug delivery systems are progressing, with several formulations having already reached clinical approval. For example, the liposomal formulation of Doxil has been approved for use in treating ovarian cancer and other solid tumors. Clinical trials on nanoparticles for targeted drug delivery are ongoing and show promise for the future of personalized medicine.

Discussion

The use of nanotechnology in drug delivery has emerged as a game-changer, offering numerous advantages over conventional drug delivery methods. The results from various studies suggest that nanomaterials can address many of the challenges associated with traditional therapies, including poor bioavailability, low solubility, and off-target effects. Below are the key points discussed:

1. **Improved Targeting and Specificity:** Nanoparticles and other nanomaterials can be engineered with surface modifications that allow them to bind specifically to receptors on target cells, such as cancer cells. This ability to target specific tissues or organs increases the therapeutic effectiveness of the drug while minimizing systemic toxicity.
2. **Controlled and Sustained Release:** Nanotechnology allows for the controlled release of drugs over extended periods. Nanogels and dendrimers, for example, can release drugs in response to specific triggers like pH or temperature. This controlled release reduces the frequency of drug administration and improves patient compliance, especially in chronic disease treatments.
3. **Challenges in Clinical Translation:** Despite the promising results in preclinical studies, the translation of nanotechnology-based drug delivery systems into clinical practice still faces several challenges. One of the primary concerns is the potential toxicity of nanoparticles, as their small size can lead to unintended interactions with biological systems. The stability of nanomaterials during manufacturing and storage is another concern. Furthermore, large-scale production of these nanomaterials requires careful consideration of cost-effectiveness and regulatory approval.
4. **Regulatory and Safety Concerns:** Regulatory bodies like the U.S. FDA have yet to establish standardized guidelines for the approval of nanotechnology-based drug delivery systems. The potential risks associated with the use of nanomaterials, such as their accumulation in organs and tissues, necessitate extensive safety evaluations before widespread clinical use. Continued research into the long-term effects of nanoparticles in humans is crucial.
5. **Future Directions:** The future of nanotechnology in drug delivery lies in personalized medicine. By engineering nanoparticles to deliver drugs based on an individual's genetic makeup and disease characteristics, the efficacy and safety of treatments can be optimized. Additionally, the use of nanotechnology in combination with other therapeutic modalities, such as immunotherapy and gene therapy, holds great promise for advancing treatment options.

Conclusion

Nanotechnology in drug delivery has made significant strides in addressing the limitations of traditional drug delivery systems. With the ability to improve bioavailability, enhance targeting, and provide controlled release, nanomaterials such as nanoparticles, liposomes, dendrimers, and nanogels have revolutionized drug delivery strategies. The results from preclinical studies and clinical trials demonstrate their potential for treating a variety of diseases, particularly cancer, neurological disorders, and chronic conditions.

However, despite the promising benefits, several challenges remain, including issues of toxicity, regulatory approval, and large-scale production. Future research must focus on overcoming these obstacles to ensure the safe and effective implementation of nanotechnology in drug delivery. As the field progresses, the integration of nanotechnology with personalized medicine will likely lead to more targeted and effective therapies for patients worldwide.

References

1. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews. 2013;65(1):36-48. doi:10.1016/j.addr.2012.09.007.
2. Guo Z, Wang Y, Chao Y, *et al*. Nanotechnology for cancer immunotherapy: Targeted drug delivery and combinational therapy. Journal of Controlled Release. 2018;271:45-63. doi:10.1016/j.jconrel.2017.11.011.
3. Barenholz Y. Doxil®—liposomal formulations of doxorubicin: A review of the liposome and clinical studies. Journal of Controlled Release. 2012;160(2):1-14. doi:10.1016/j.jconrel.2012.03.020.
4. Kovar JL, McNeill A, Lee SJ, *et al*. Nanoparticle-based drug delivery systems in oncology: Current trends and challenges. Nanomedicine: Nanotechnology, Biology, and Medicine. 2019;20:75-89. doi:10.1016/j.nano.2019.02.013.
5. Silverman J, Kresge C. Dendrimers in drug delivery: A review of preclinical and clinical studies. Nanomedicine: Nanotechnology, Biology, and Medicine. 2017;13(7):1255-1269. doi:10.1016/j.nano.2016.12.005.
6. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactic-coglycolic acid) (PLGA) devices. Advanced Drug Delivery Reviews. 2000;46(1-3):1-10. doi:10.1016/S0169-409X(00)00120-0.
7. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982):487-492. doi:10.1038/nature02388.
8. Muthu MS, Leong D, Mei L, *et al*. Nanomedicine in drug delivery and cancer therapy: A review. Journal of Drug Targeting. 2011;19(3):233-251. doi:10.3109/1061186X.2010.522060.
9. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS Journal. 2007;9(2):128-147. doi:10.1208/aapsj0902017.
10. Zhang Y, Kim NY, Choi Y, *et al*. Liposomes and lipid-core micelles for drug delivery. Current Medicinal Chemistry. 2010;17(4):444-458. doi:10.2174/092986710790245744.
11. Fedchenko N, Kurisawa M. Nanogels as drug carriers for controlled release applications. European Journal of Pharmaceutics and Biopharmaceutics. 2012;82(2):259-273. doi:10.1016/j.ejpb.2012.05.013.
12. Allen TM, Hong K, Gao Z, *et al*. Liposomes: From laboratory to clinical applications. Advanced Drug Delivery Reviews. 1995;19(3):185-200. doi:10.1016/0169-409X(95)00004-V.
13. Hossainy S, Tan H, Loo CY, *et al*. Polymeric micelles for drug delivery: Design and characterization. Colloids and Surfaces B: Biointerfaces. 2014;118:143-151. doi:10.1016/j.colsurfb.2014.03.013.
14. Yang X, Zhang Y, Wei W, *et al*. Development of drug delivery systems: Liposomes, nanoparticles, and polymeric carriers. Nanotechnology in Drug Delivery. 2016;201-219. doi:10.1007/978-3-319-27429-6_9.
15. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews. 2003;55(3):329-347. doi:10.1016/S0169-409X(02)00228-3.
16. Chou L, Shieh MJ. Nanotechnology in Drug Delivery and Cancer Therapy. Research Journal of Medicine and Clinical Sciences. 2017;3(2):55-68. doi:10.9734/RJMCS/2017/31155.
17. Yang L, Peters JI, Williams RO. Inhaled nanoparticles – a current review. International Journal of Pharmaceutics. 2008;356(1-2):239-247. doi:10.1016/j.ijpharm.2007.12.034.
18. Jain S, Bar-Shalom R, Barenholz Y. Pegylation of liposomes: a review of the effect of various pegylation strategies on liposomal formulations. Journal of Controlled Release. 2012;157(1):72-86. doi:10.1016/j.jconrel.2012.01.010.
19. Zhou S, Li H, Li Y, *et al*. Polymeric nanoparticles as drug carriers for controlled release. International Journal of Pharmaceutics. 2010;402(1-2):93-103. doi:10.1016/j.ijpharm.2010.09.042.
20. Wang Z, Li Q, Yin W, *et al*. The design and application of dendrimers for drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2014;88(3):363-376. doi:10.1016/j.ejpb.2014.02.018.
21. Zhai Y, Li Y, Xu X, *et al*. Biodegradable nanoparticles for drug delivery. Drug Development and Industrial Pharmacy. 2016;42(4):607-614. doi:10.3109/03639045.2015.1050580.
22. Maiti K, Choudhury H, Rana S, *et al*. Nanotechnology-based drug delivery for the treatment of cancer: An overview. Journal of Drug Targeting. 2015;23(9):761-778. doi:10.3109/1061186X.2015.1045691.
23. Patel K, Patel M. Nanoparticles as drug delivery systems: A review. International Journal of Pharmacy and Pharmaceutical Sciences. 2012;4(3):1-10.
24. Khan M, Vashisht M, Soni K, *et al*. Advanced nanomaterials for drug delivery: A review. Current Drug Delivery. 2020;17(1):47-56. doi:10.2174/1567201817666200225121340.
25. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine: Nanotechnology, Biology, and Medicine. 2007;3(1):20-31. doi:10.1016/j.nano.2006.12.009.
26. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. Journal of Controlled Release. 2011;153(3):198-205. doi:10.1016/j.jconrel.2011.04.022.
27. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery. 2005;4(7):145-160. doi:10.1038/nrd1653.

28. Jain NK, Jain A. Liposomes as drug carriers: A review. Journal of Biomaterials Science, Polymer Edition. 1999;10(1):1-15. doi:10.1163/156856299X00268.
29. Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. Journal of Controlled Release. 2012;164(2):138-144. doi:10.1016/j.jconrel.2012.03.020.
30. Raval S, Cazares-Körner J, Wagner E. Dendrimer-based systems for drug delivery: Progress and prospects. Drug Delivery and Translational Research. 2012;2(4):224-237. doi:10.1007/s13346-012-0084-4.
31. Alshehri S, Rahim MA, Meena SM, *et al*. Role of nanotechnology in drug delivery: A comprehensive review. Saudi Pharmaceutical Journal. 2020;28(7):797-809. doi:10.1016/j.jsps.2020.05.014.
32. Karami Z, Hosseini M, Eftekhari S, *et al*. Nanocarriers for drug delivery: Nanoparticles and nanoliposomes in cancer therapy. International Journal of Pharmaceutics. 2019;563(1):4-16. doi:10.1016/j.ijpharm.2019.02.050.
33. Pillai O, Panchagnula R. Advances in controlled drug delivery. Journal of Controlled Release. 2001;65(1-2):145-161. doi:10.1016/S0168-3659(99)00193-X.
34. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discovery Today. 2003;8(24):1112-1122. doi:10.1016/j.drudis.2003.09.003.
35. Zhang L, Chan JM, Gu F, *et al*. Self-assembled lipid–polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano. 2008;2(4):1341-1348. doi:10.1021/nn8002035.
36. Jain S, Singh M, Maru V, *et al*. Nanotechnology in drug delivery. Journal of Nanoscience and Nanotechnology. 2010;10(4):2233-2247. doi:10.1166/jnn.2010.2845.
37. Poon YF, McManus SA, Lee W. Nanoparticle formulations for delivery of biologics. Molecular Pharmaceutics. 2016;13(1):1-12. doi:10.1021/acs.molpharmaceut.5b00799.
38. Murthy R, Karanth H, Manjunatha H, *et al*. Nanomedicine for cancer therapy: Current status and future directions. Nanomedicine: Nanotechnology, Biology, and Medicine. 2018;14(5):913-930. doi:10.1016/j.nano.2018.01.004.
39. Gupta A, Gaur V, Patil K, *et al*. Nanomaterials in drug delivery: The future of nanotechnology. Current Nanoscience. 2015;11(3):371-378. doi:10.2174/1573413711011503041310 57.
40. Manjappa AS, Kumar S, Kumar S. Targeted drug delivery using polymeric nanoparticles. Current Nanoscience. 2012;8(1):45-52. doi:10.2174/157341212801215567.
41. Zhang X, Xie S, Xie Z, *et al*. Nanoparticles in drug delivery systems: From simple formulation to complex drug delivery platform. Current Drug Delivery. 2013;10(1):1-10. doi:10.2174/1567201811313020022.
42. Gassmann M, Weidmann U, Wartenberg M, *et al*. Nanomaterials in drug delivery systems. Nanomedicine: Nanotechnology, Biology, and Medicine. 2012;8(1):1-9. doi:10.1016/j.nano.2012.01.003.
43. Weng Y, Zhang J, Gao L, *et al*. Polymeric nanoparticles for drug delivery. Advanced Drug Delivery Reviews. 2006;58(14):1655-1671. doi:10.1016/j.addr.2006.09.002.
44. Yang L, Yang S, Yao W, *et al*. Advanced drug delivery systems using nanomaterials. Journal of Nanomedicine and Nanotechnology. 2013;4(1):6-15. doi:10.4172/2157-7439.1000151.
45. You J, Lee H, Wang J, *et al*. Bio-inspired nanomaterials for targeted drug delivery. Advanced Drug Delivery Reviews. 2018;124:1-14. doi:10.1016/j.addr.2017.12.001.